This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2021. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.
~$51 Million net NERLYNX revenue in Q4’21
3,454 Ex-factory bottles were sold in Q4’21

Bottles Sold (SP + SD) by Quarter

Includes Commercial SP and SD
~60% of patients in Q4’21 started at a reduced dose* **

*Reduced dose defined as fewer than 6 pills per day

** FDA approved dose-escalation label supplement in June 2021
# Rest of World Partnerships – Timelines

<table>
<thead>
<tr>
<th>Region</th>
<th>Partner</th>
<th>Regulatory Approvals</th>
<th>Commercial Launches</th>
</tr>
</thead>
</table>
| Australia / SE Asia     | Specialised Therapeutics | • 2019 – Ext. Adj. in Australia, Singapore  
• 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand | • 2020 – Singapore  
• Q2 2021 – Malaysia  
• Q3 / Q4 2021 – Brunei, New Zealand |
| Israel                  | MEDISON          | • 2020 – Approved in Ext. Adj. and mBC                                              | • 2020 – Launched                                         |
| Canada                  | Knight           | • 2019 – Ext. Adj. approved  
• Q2 2021 – mBC approved                                                           | • 2020 – Launched                                         |
| Latin America           | PINT PHARMA      | • 2019 – Ext Adj in Argentina  
• 2020 – Ext. Adj in Chile, Ecuador  
• 2020 – mBC in Argentina  
• 2021 – Ext Adj and mBC in Peru; mBC in Chile  
• Q4 2021 – Ext. Adj. in Brazil  
• Q1 2022 – Ext. Adj. in Mexico | • 2020 – Argentina  
• Q2 2021 – Chile  
• Q4 2021 – Peru |
| Europe                  | Pierre Fabre     | • 2019 – EMA approval  
• 2019 – Ext. Adj. in Hong Kong  
• 2020 – Ext. Adj. in China, Taiwan  
• Q4 2021 – mBC in Taiwan                                                   | • 2019 – Germany, UK, Austria  
• 2020 – Sweden, Finland, Scotland, Switzerland, Denmark  
• 2020 – Hong Kong  
• Q1 2021 – China (added to 2021 NRDL), Taiwan  
• Q1 2021 – Greece, Czech Republic |
| Greater China           | BIONIK           | • Q4 2021 – Ext. Adj. in S. Korea                                                    | • Q1 2022 – Launched                                     |
| Middle East             |                  |                                                                                       |                                                          |
| North and West Africa   |                  |                                                                                       |                                                          |
| South Africa            |                  |                                                                                       |                                                          |
| Turkey                  |                  |                                                                                       |                                                          |
Puma Biotechnology
Earnings Call
Commercial Update

March 3, 2022